LOS ANGELES, Nov. 17, 2017 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that it plans to report third quarter 2017 financial
results on Tuesday, November 21,
2017. The Company also plans to hold a conference call and
webcast on that day at 5:00 pm ET to
discuss the third quarter 2017 financial results and provide a
business update. The call will be hosted by Anthony Gringeri, PhD, President and CEO.
|
LIVE CALL:
|
(877) 853-5636
(toll-free); international dial-in: (631) 291-4544; conference code
3689426.
|
|
|
WEBCAST:
|
Interested parties
who wish to listen to the webcast should visit the Investor
Relations section of ImmunoCellular's website at www.imuc.com,
under the Events and Presentations tab. A replay of the webcast
will be available one hour after the conclusion of the
event.
|
The conference call will contain forward-looking statements. The
information provided on the teleconference is accurate only at the
time of the conference call, and ImmunoCellular will take no
responsibility for providing updated information except as required
by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based
therapies for the treatment of cancer. ImmunoCellular is focused on
advancing its Stem-to-T-Cell research program, which engineers
hematopoietic stem cells to generate cytotoxic T cells. Additional
assets, for which the Company is seeking partners, include
clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are
patient-specific, dendritic cell-based immunotherapies targeting
solid tumors. To learn more about ImmunoCellular, please visit
www.imuc.com.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
267.457.3734 direct
415.652.4819 mobile
jane@jmgcomm.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-report-third-quarter-2017-financial-results-on-november-21-2017-300558273.html
SOURCE ImmunoCellular Therapeutics, Ltd.